# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 19 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT S6a2b1a0656
CUTOFF DATE (today): 2021-10-27
Regulator: FDA (US)
Matter: FDA draft guidance: Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Se4622d93fc
CUTOFF DATE (today): 2025-12-10
Regulator: SEBI (IN)
Matter: SEBI consultation: permitting debt issuers to offer incentives to certain categories of investors in public issues
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Safdd2f0821
CUTOFF DATE (today): 2026-06-12
Regulator: SEBI (IN)
Matter: SEBI consultation: extending the early pay-in margin benefit to options contracts in the commodity derivatives segment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-05 | official-forward (B) | draft_circular_for_comment | "Consultation Paper on Draft Circular on Clarification with respect to Applicability of the benefit of Early Pay-In in Commodity Derivatives Segment" | www.sebi.gov.in
   Claims: Proposes to extend the early pay-in (EPI) benefit -- currently available only for futures contracts in the commodity derivatives segment -- to options contracts as well. / Describes the existing rule (Master Circular Para 11.3) under which stock exchanges provide an early pay-in facility exempting market participants who deposit certified goods early from certain margins on futures contracts. / States the proposal follows stakeholder representations and was examined by the Working Group on Review of the delivery/settlement framework for Agricultural Commodity Derivatives and by the Commodity Derivatives Advisory Committee (CDAC).
   Excerpt: This consultation paper seeks comments from the public and stakeholders on the proposal to extend the applicability of the benefit of early pay-in, currently available on futures contracts, to options contracts in the commodity derivatives segment. Para 11.3 of Chapter 11 of SEBI Master Circular... for Commodity Derivatives Segment dated Aug 04, 2023 prescribes norms for Early Pay-in Facility in respect of commodity derivatives... SEBI has received representations with respect to the aforementioned provisions, stating that the early pay-in (EPI) benefit is currently available only in respect of futures contracts. It has been requested that the EPI benefit may be also made applicable on options contracts.
---
## SNAPSHOT Sb32eac608c
CUTOFF DATE (today): 2026-02-10
Regulator: SEBI (IN)
Matter: SEBI consultation: aligning Trading Member position limits in the Equity Derivatives Segment with the client-level Futures-Equivalent metric
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S0e3e441b51
CUTOFF DATE (today): 2023-03-14
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-01-13 | official-forward (B) | draft_guidance_availability_notice | "Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters-- Premarket Notification (510(k)) Submissions; Draft Guidance for Industry and Food and Drug Administration S
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters-- Premarket Notification (510(k)) Submissions; Draft Guidance for Industry and Food and Drug Administration Staff." The FDA is issuing this draft guidance document to provide recommendations for 510(k) submissions for peripheral percutaneous transluminal angioplasty (PTA) balloons and specialty catheters (e.g., infusion catheters, PTA balloon catheters for in-stent restenosis (ISR), scoring/cutting balloons). This draft guidance is not final nor is it in effect at this time.
---
## SNAPSHOT S011a48c150
CUTOFF DATE (today): 2025-07-08
Regulator: FDA (US)
Matter: FDA draft guidance: Benefit-Risk Considerations for Product Quality Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S845b3e5899
CUTOFF DATE (today): 2024-11-03
Regulator: FDA (US)
Matter: FDA draft guidance: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning-Enabled Device Software Functions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-03-30 | official-forward (B) | draft_guidance_availability_notice | "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning-Enabled Device Software Functions; Draft Guidance for Industry and Food and Drug Administration St" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions." This draft guidance de
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions." This draft guidance demonstrates FDA's commitment to developing innovative approaches to the regulation of machine learning- enabled medical devices and describes an approach that would often be the least burdensome and would support iterative improvement through modifications to machine learning-enabled device software functions (herein referred to as ML-DSF) while continuing to ensure device safety and effectiveness. This draft guidance provides recommendations on the information to be included in a Predetermined Change Control Plan (PCCP) in a marketing submission for an ML-DSF. Such a plan describes the anticipated ML-DSF modifications and the associated methodology to implement those modifications, which would be reviewed in the marketing submission to ensure the continued safety and effectiveness of the device without necessitating additional marketing submissions for each modification described in the
---
## SNAPSHOT Sbcef061d7f
CUTOFF DATE (today): 2026-02-21
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing minimum investment in Social Impact Funds and NPO registration/minimum-subscription requirements on the Social Stock Exchange
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-09 | official-forward (B) | consultation_paper | "Review of minimum value of investment by individual investors in Social Impact Fund under SEBI AIF Regulations, 2012 and review of requirements related to registration period of NPOs and minimum subscription under SEBI I" | www.sebi.gov.in
   Claims: Proposes to reduce the minimum value of investment by individual investors in Social Impact Funds (AIF Regulations) from the existing rupees two lakh to rupees one thousand. / Notes the proposed rupees-one-thousand figure would align the Social Impact Fund minimum with the minimum application size already prescribed (from March 19, 2025) for Zero Coupon Zero Principal (ZCZP) instruments under ICDR Regulations. / Proposes related changes to NPO registration-period requirements and minimum-subscription requirements under ICDR Regulations, 2018 for the Social Stock Exchange. / States the objective is to facilitate wider retail participation on the Social Stock Exchange.
   Excerpt: The objective of this consultation paper is to solicit comments / views / suggestions from the public and other stakeholders on the proposals relating to review of minimum value of investment in Social Impact Funds and the requirement of minimum subscription and registration period for Not for Profit Organizations on Social Stock Exchange under the relevant SEBI Regulations... it is proposed that the minimum value of investment by individual investors in Social Impact Fund of AIF may be reduced from the existing rupees two lakh to rupees one thousand.
---
## SNAPSHOT Sf448233379
CUTOFF DATE (today): 2023-05-18
Regulator: FDA (US)
Matter: FDA draft guidance: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb974b966a5
CUTOFF DATE (today): 2026-04-29
Regulator: SEBI (IN)
Matter: SEBI consultation: modifying nomination norms for demat accounts and mutual fund folios
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-03-17 | official-forward (B) | consultation_paper | "Consultation Paper on Modified norms for Nomination in Demat accounts and Mutual Fund Folios" | www.sebi.gov.in
   Claims: Seeks comments on modifying the January 10, 2025 nomination-facility circular for demat accounts and mutual fund folios, aligning more closely with banking-sector nomination norms. / Proposes dropping the facility empowering a nominee to operate an account/folio while the investor is alive but incapacitated, citing high implementation cost, audit-trail difficulty, and fraud/misuse/legal-dispute risk. / Notes certain provisions of the January 2025 circular were already deferred by a December 11, 2025 circular due to operational challenges.
   Excerpt: This Consultation Paper seeks comments / suggestions from the public to modify the circular on 'Revise and revamp Nomination Facilities in the Indian Securities Market' ('Circular') dated January 10, 2025, in order to enhance the ease of investor on-boarding and ease the nomination process by aligning with the banking norms on nomination. SEBI issued the circular on January 10, 2025 for demat accounts and MF folios, w.e.f. March 01, 2025. To address certain operational challenges, the implementation of certain provisions of the circular were deferred vide circular dated December 11, 2025.
---
## SNAPSHOT S0f6e12a5bf
CUTOFF DATE (today): 2024-04-22
Regulator: FDA (US)
Matter: FDA draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sbd8ed1b85b
CUTOFF DATE (today): 2024-09-09
Regulator: FDA (US)
Matter: FDA draft guidance: Mpox: Development of Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S9e554a1529
CUTOFF DATE (today): 2026-02-21
Regulator: SEBI (IN)
Matter: SEBI consultation: permitting net settlement of funds for Foreign Portfolio Investor cash-market transactions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S71af9b3399
CUTOFF DATE (today): 2022-07-15
Regulator: FDA (US)
Matter: FDA draft guidance: Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sf949386a6b
CUTOFF DATE (today): 2022-01-15
Regulator: FDA (US)
Matter: FDA draft guidance: Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-07-01 | official-forward (B) | draft_guidance_availability_notice | "Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Instructions for Use--Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products--Content and Format." This dr
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Instructions for Use--Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products--Content and Format." This draft guidance provides recommendations for developing the content and format of an Instructions for Use (IFU) document for human prescription drugs and biological products and drug-device or biologic-device combination products submitted under a new drug application (NDA) or a biologics license application (BLA). The IFU is developed by applicants for patients who use drug products that have complicated or detailed patient-use instructions. The recommendations in this draft guidance are intended to help develop consistent content and format across IFUs and to help ensure that patients receive clear, concise information that is easily understood for the safe and effective use of prescription drug products.
---
## SNAPSHOT S2d78b7e5ce
CUTOFF DATE (today): 2021-06-12
Regulator: FDA (US)
Matter: FDA draft guidance: Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S7ffe83f88e
CUTOFF DATE (today): 2022-07-19
Regulator: FDA (US)
Matter: FDA draft guidance: General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S3f090b5d45
CUTOFF DATE (today): 2026-09-17
Regulator: SEBI (IN)
Matter: SEBI consultation: enhancements to the Straight-Through Processing framework for institutional trade messaging
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Saf64de60e9
CUTOFF DATE (today): 2026-08-05
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing use of historical price scenarios in stress testing for the Commodity Derivatives Segment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.